Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia

Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia

Abstract Background Ofatumumab (Arzerra®, Novartis) is a treatment for chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab [double refractory (DR-CLL)]. Ofatumumab was licensed on the basis of an uncontrolled Phase II study, Hx-CD20-406, in which patients receiving ofatumumab surv...

Full description

Bibliographic Details
Main Authors: Anthony J. Hatswell, Gwilym J. Thompson, Penny A. Maroudas, Oleg Sofrygin, Thomas E. Delea
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Historical control
Cost-utility
Uncontrolled study
Online Access:http://link.springer.com/article/10.1186/s12962-017-0071-x

Internet

http://link.springer.com/article/10.1186/s12962-017-0071-x

Similar Items